Widerstand gegen Chemo - Neuer Resistenzmechanismus von Krebszellen gefunden 24.10.2012 Pressemitteilung, Uniklinik Köln Wissenschaftler der Uniklinik Köln haben einen neuen Mechanismus entdeckt, der es Krebszellen ermöglicht, eine Chemotherapie ungeschadet zu überstehen.
Die gemeinsame Arbeit der Arbeitsgruppen von Prof. Thomas Benzing, Direktor der Klinik II für Innere Medizin und Prof. Christian Reinhardt, Professor für klinische und molekulare Onkologie, Klinik I für Innere Medizin, wurde nun im renommierten Fachjournal EMBO-Journal veröffentlicht. Chemotherapie ist trotz intensiver Forschung in vielen verschiedenen Krebsarten weiterhin nur schlecht wirksam. Prof. Das internationale Forscherteam aus Deutschland, USA und den Niederlanden befasste sich in seinen Arbeiten mit dem Protein p53, welches gemeinhin auch als „Wächter des Genoms“ beschrieben wird.
Tumorzellen finden verschiedene Wege, um die Aktivität von p53 zu umgehen. Es gibt aber auch Tumoren, die einen Teil der p53 Funktion nutzen, um Chemotherapie-Resistenz zu entwickeln. Paper: Gene Expression Profiling (GEP) of Whole Bone Marrow Biopsies in Complete Remission (BMB-CR) of Multiple Myeloma (MM) Patients Treated On Total Therapy Protocols – Normalization of GEP Signature in Comparison with Normal Donor BMB (BMB-NL) and Con. Oral and Poster Abstracts Oral 651.
Myeloma - Biology and Pathophysiology, excluding Therapy: Genomic and Molecular Determinant of Outcome in Myeloma Thomas Murphy Ballroom 1, Level 5, Building B (Georgia World Congress Center) Paper: Genome-Wide Methylation and Gene Expression Analyses Identify Patients At High and Low Risk of Disease Progression. Introduction Outcome in multiple myeloma (MM) is heterogeneous and the assessment of individual risk based on molecular features is essential to make personalised therapy possible.
Epigenetic modifications contribute to individual tumour biology and, consequently, clinical behaviour. Here, we present data on the association between differential methylation, gene expression and survival in 161 newly-diagnosed MM patient samples. The aim of the study is to provide novel insights based on genome wide data into the epigenetic biology of myeloma as well as to define prognostically relevant epigenetic markers. Patients and Methods Methylation data from Illumina Infinium HumanMethylation27 BeadChips for 161 presentation MM samples was used for the analysis. Results Using a logistic regression model testing, we defined genes for which differential methylation was associated with differences in overall survival (OS). Discussion. Paper: Metaphase Cytogenetic Abnormality (CA) Subtypes in Multiple Myeloma (MM) Treated with Front Line Total Therapy (TT) Protocols TT1, TT2, TT3, TT4 and TT5.
Oral and Poster Abstracts Oral 651.
Myeloma - Biology and Pathophysiology, excluding Therapy: Genomic and Molecular Determinant of Outcome in Myeloma Thomas Murphy Ballroom 1, Level 5, Building B (Georgia World Congress Center) Frits van Rhee, MD, PhD1, Jeffrey R Sawyer, Ph.D.2*, Saad Z Usmani, MD FACP1, Sarah Waheed, MD1, Christoph Heuck, MD1, Alan Mitchell3*, Antje Hoering, PhD3* and Bart Barlogie, MD, PhD1 1Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR2Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR3Research and Biostatistics, Cancer Research and Biostatistics, Seattle, WA We have previously reported on the adverse prognostic implications of CA, independently contributing to clinical outcome prediction even in the era of gene expression profiling (GEP). Disclosures: No relevant conflicts of interest to declare. *signifies non-member of ASH.